Examples of using Caution is advised in English and their translations into Croatian
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
Caution is advised in these patients see section 4.4.
No dose adjustment is suggested but caution is advised in patients with moderate hepatic impairment.
Caution is advised in patients with history of hyperuricaemia or gouty arthritis.
No dose adjustment of Eviplera is suggested but caution is advised in patients with moderate hepatic impairment.
Caution is advised as folinic acid is known to enhance the activity of 5-FU.
People also translate
The efficacy of lamivudine in patients co-infected with Delta hepatitis orhepatitis C has not been established and caution is advised.
Caution is advised as co-administration may increase the toxicity of Teysuno.
A potential effect on CYP2D6 isoenzyme cannot be excluded and caution is advised for patients who receive medicinal products that are CYP2D6 substrates.
Therefore, caution is advised when administering Eurartesim to these patients see section 4.4.
Possible implications for the in vivo situation have not been investigated, but caution is advised when cangrelor is to be combined with a BCRP substrate.
Caution is advised during co-administration with CYP2B6 substrates e.g. bupropion, efavirenz, cyclophosphamide.
No dose adjustment is recommended for patients with mild to severe hepatic impairment but caution is advised due to the potential for higher plasma exposure.
Therefore, caution is advised when Jentadueto is used in combination with a sulphonylurea and/or insulin.
There is limited experience with ticagrelor in patients with moderate hepatic impairment,therefore, caution is advised in these patients see sections 4.2 and 5.2.
Therefore, caution is advised during injection of ADVATE reconstituted in 2 ml sterilised water for injections, especially in children.
Effects on unbound exposure could be expected(has not been studied)and therefore caution is advised in patients with moderate hepatic impairment.
Caution is advised when using medicinal products such as antihypertensives and/or cardiac glycosides concomitantly with SIMBRINZA.
Sufentanil is excreted in human milk when applied intravenously;therefore caution is advised when Zalviso is administered to breast-feeding women.
Therefore, caution is advised when daptomycin is co- administered with any other medicinal product known to reduce renal filtration.
The possibility of elevated asenapine plasma levels cannot be excluded in some patients with moderate hepatic impairment(Child-Pugh B) and caution is advised.
Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Copalia HCT, 10 mg/320 mg/25 mg.
Due to possible additive pharmacodynamic effects(myelotoxicity), caution is advised as co- administration may increase the risk and severity of haematologic toxicity of Teysuno.
Caution is advised in patients with creatinine clearance below 30 ml/min as there is no experience of pazopanib in this patient population.
Specific interaction studies with lidocaine/prilocaine and anti-arrhythmic medicinal products class III(e.g. amiodarone)have not been performed, but caution is advised see also section 4.4.
Caution is advised in patients with creatinine clearance below 30 ml/min as there is no experience of pazopanib in this patient population see section 4.2.
However epidemiological data from the post-marketing experience shows an increased risk of fractures in both men and women and caution is advised in patients with long term treatment.
Caution is advised due to the possibility of an additive or potentiating effect with CNS depressants e.g. alcohol, barbiturates, opiates, sedatives, or anaesthetics.
In patients treated with Zontivity the concomitant use of heparin(including LMWH)might be associated with an increased risk of bleeding and caution is advised. See section 4.4.
Particular caution is advised in such cases where posaconazole is administered peripherally, as the recommended infusion time of 30 minutes may further increase Cmax.
No dose adjustment of CRESEMBA is necessary when co- administered with strong CYP3A4/5 inhibitors,however caution is advised as adverse drug reactions may increase see section 4.5.
